We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AM-Pharma has announced the enrolment of first participants in an exploratory cohort in Phase III REVIVAL pivotal trial of its human recombinant alkaline phosphatase (AP) for treating patients with Covid-19 and sepsis-associated acute kidney injury.